2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3012 CD21^low B cells: An emerging population in the pathogenesis of primary immune thrombocytopenia

Cristina Giubbilei, MD, Alessio Mazzoni2, Sara Pratesi3, Ginevra Giustini4, Agnese Baffioni5, Valentina Carrai6
1 Hematology Unit, AOU Careggi, Florence, Italy
2 Dipartimento Medicina sperimentale e clinica, University of Florence, Florence, Italy
3 SOD Diagnostica Citofluorimetrica e Immunologica AOU Careggi, Florence, Italy
4 Hematology Unit, AOU Careggi, Florence, Italy
5 Hematology Unit, AOU Careggi, Florence, Italy
6 Hematology Unit, AOU Careggi, Florence, Italy

BackgroundThe pathogenesis of primary immune thrombocytopenia (ITP) is complex and not completely understood. Historically attributed to a Bcell–driven autoreactive milieu, it has recently been reframed within the context of autoreactive B–Tcell interactions that impair platelet production and clearance. Among candidate immunomarkers, CD21^low B cells and circulating T-follicular helper (Tfh) cells may indicate chronic activation and support autoantibody formation. We aimed to characterize peripheral blood CD21^low and Tfh in treatment-naïve patients with ITP and to assess their relationship with platelet count, compared with healthy controls and patients with non-immune thrombocytopenia.

MethodsWe conducted an observational study of 28 treatment-naïve adults with primary ITP, 14 healthy controls (HC) and 7 disease controls (DC; hereditary non-autoimmune thrombocytopenia). Peripheral blood was collected at basaline before ITP-directed treatment.Flow cytometry with standardized gating quantified B and T-cell. Pairwaise comparison among cohorts were performed using two-sided mann-whitney U tests. Associations between CD21^low or Tfh frequencies and plt count were assessed by two-sided spearman rank correlation in the combined ITP+HC population. A p-value <0.05 was considered significant.

ResultsAmong ITP patients, 16/28 (57.1%) were women; median age at diagnosis was 51.5 years [38.3–66.0]. Eighteen patients (64.3%) had chronic ITP, including acute-on-chronic disease, 2 (7.1%) persistent ITP, and 8 (28.6%) newly diagnosed ITP. Median disease duration was 3.11 years [0.06–5.53]. Median platelet counts were 53.5×10?/L [27.3–76.8] at diagnosis and 44.0×10?/L [21.3–63.5] at sampling. Bleeding manifestations according to WHO-Bleeding Scale were present in 5/28 patients (17.9%). 13 patients (46.4%) received first-line treatment after sampling; among them, 8/13 (61.5%) achieved complete response, 3/13 (23.1%) partial response, and 2/13 (15.4%) no response. As expected, platelet counts were markedly higher in HC than in both ITP and DC (265.0 [233.5–308.5] vs 44.0 [21.3–63.5] and 23.0 [21.0–64.0] ×10?/L, respectively; both p<0.001), whereas no significant difference was observed between ITP and DC (p=0.967). CD21^low  frequencies were significantly higher in ITP than in HC: 8.35% [5.60–12.75] vs 4.90% [4.13–5.93] (p=0.008). DC showed intermediate values, 5.10% [3.65–7.80] (p=0.04). Tfh frequencies were numerically higher in ITP than in HC, 11.60% [8.05–16.23] vs 8.45% [7.58–9.55], but the difference did not reach statistical significance (p=0.0547).DC showed a median Tfh frequency of 9.00% [8.20–15.10], with no significant difference versus ITP (p=0.9507) or HC (p=0.3703).In the combined ITP+HC population (n=42), CD21^low frequency showed inverse correlation with platelet count (Spearman ρ=−0.405, p=0.0078), whereas the correlation between Tfh and platelet count wasn’t significant (ρ=−0.251, p=0.108)

Conclusion In treatment-naive ITP, CD21low were significantly expanded vs HC and inversely correlated with platelet count, supporting a role for chronic B-cell activation in disease pathophysiology. Tfh cells showed a concordant but non-significant trend, likely reflecting limited statistical power rather than a true absence of effect. These findings put CD21low on evidence as a intriguing biomarker of disease in ITP, while Tfh requires further validation. Larger cohorts are needed to clarify whether CD21low/Tfh reflect an ITP-specific feature.

Cristina Giubbilei, MD: No relevant conflicts of interest to declare.